CarreĆ³n-Guarnizo, Ester et al "Safety of Rituximab as First-line Therapy in Neuromyelitis Optica (NMO) and NMO-spectrum Disorders: Five Years of Experience (P5.264)." Neurology 84.14 Supplement (2015): P5.264. Web. 29 May. 2020.